Latest News and Press Releases

OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizuresData demonstrate OV329 has the potential for an improved...

Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor, and initiating Phase 1 trials in the fourth quarter of 2022Data supporting...

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...

Ovid executing on its strategy to build a leading epilepsy pipelineOV329 expected to enter the clinic in 2022Organization reshaped to reduce personnel by 20% and increase operational...

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by...

– Ovid to License Gaboxadol to Healx – – Healx to Explore Gaboxadol in Combination Therapies for Fragile X, Other Indications – NEW YORK, N.Y. and CAMBRIDGE, United Kingdom, Feb. 08, 2022 (GLOBE...

Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic therapiesCollaboration with Dr. Stephen Moss,...

Ovid is implementing its business development program which intends to secure a series of opportunities that complement and enhance its pipeline of precision and small-molecule CNS medicinesA...

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological...